Co-Authors
This is a "connection" page, showing publications co-authored by Athol Wells and Anand Devaraj.
Connection Strength
2.083
-
Residual Lung Disease at Six-month Follow-up CT after COVID-19: Clinical Significance Is a Key Issue. Radiology. 2021 11; 301(2):E406-E408.
Score: 0.959
-
Interstitial Lung Disease after COVID-19 Infection: A Catalog of Uncertainties. Radiology. 2021 04; 299(1):E216-E218.
Score: 0.232
-
COVID-19 related lung pathology: old patterns in new clothing? Histopathology. 2020 08; 77(2):169-172.
Score: 0.224
-
The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions. Lancet Respir Med. 2020 05; 8(5):438-440.
Score: 0.218
-
Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis. Eur Respir J. 2019 07; 54(1).
Score: 0.209
-
In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality. Eur Respir J. 2019 05; 53(5).
Score: 0.052
-
Variable radiological lung nodule evaluation leads to divergent management recommendations. Eur Respir J. 2018 12; 52(6).
Score: 0.050
-
Rapidly Progressive Cystic Lung Disease. Am J Respir Crit Care Med. 2018 07 15; 198(2):264.
Score: 0.049
-
Pleuroparenchymal Fibroelastosis: A Review of Histopathologic Features and the Relationship Between Histologic Parameters and Survival. Am J Surg Pathol. 2017 Dec; 41(12):1683-1689.
Score: 0.047
-
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017; 4(1):e000212.
Score: 0.046